Open AccessThis article is
- freely available
Androgen Receptor Phosphorylation at Serine 308 and Serine 791 Predicts Enhanced Survival in Castrate Resistant Prostate Cancer Patients
Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK
Pathology Department, Southern General Hospital, 1345 Govan Road, Glasgow G51, UK
Department of Urology, Royal Infirmary, Glasgow G31 2ER, UK
* Author to whom correspondence should be addressed.
Received: 22 April 2013; in revised form: 22 July 2013 / Accepted: 26 July 2013 / Published: 13 August 2013
Abstract: We previously reported that AR phosphorylation at serine 213 was associated with poor outcome and may contribute to prostate cancer development and progression. This study investigates if specific AR phosphorylation sites have differing roles in the progression of hormone naïve prostate cancer (HNPC) to castrate resistant disease (CRPC). A panel of phosphospecific antibodies were employed to study AR phosphorylation in 84 matched HNPC and CRPC tumours. Immunohistochemistry measured Androgen receptor expression phosphorylated at serine residues 94 (pAR94), 308 (pAR308), 650(pAR650) and 791 (pAR791). No correlations with clinical parameters were observed for pAR94 or pAR650 in HNPC or CRPC tumours. In contrast to our previous observation with serine 213, high pAR308 is significantly associated with a longer time to disease specific death (p = 0.011) and high pAR791 expression significantly associated with a longer time to disease recurrence (p = 0.018) in HNPC tumours and longer time to death from disease recurrence (p = 0.040) in CRPC tumours. This observation in CRPC tumours was attenuated in high apoptotic tumours (p = 0.022) and low proliferating tumours (p = 0.004). These results demonstrate that understanding the differing roles of AR phosphorylation is necessary before this can be exploited as a target for castrate resistant prostate cancer.
Keywords: androgen receptor; phosphorylation; hormone naive prostate cancer; castrate resistant prostate cancer
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
McCall, P.; Adams, C.E.; Willder, J.M.; Bennett, L.; Qayyum, T.; Orange, C.; Underwood, M.A.; Edwards, J. Androgen Receptor Phosphorylation at Serine 308 and Serine 791 Predicts Enhanced Survival in Castrate Resistant Prostate Cancer Patients. Int. J. Mol. Sci. 2013, 14, 16656-16671.
McCall P, Adams CE, Willder JM, Bennett L, Qayyum T, Orange C, Underwood MA, Edwards J. Androgen Receptor Phosphorylation at Serine 308 and Serine 791 Predicts Enhanced Survival in Castrate Resistant Prostate Cancer Patients. International Journal of Molecular Sciences. 2013; 14(8):16656-16671.
McCall, Pamela; Adams, Claire E.; Willder, Jennifer M.; Bennett, Lindsay; Qayyum, Tahir; Orange, Clare; Underwood, Mark A.; Edwards, Joanne. 2013. "Androgen Receptor Phosphorylation at Serine 308 and Serine 791 Predicts Enhanced Survival in Castrate Resistant Prostate Cancer Patients." Int. J. Mol. Sci. 14, no. 8: 16656-16671.